Modality
ASO
MOA
JAK1/2i
Target
FXIa
Pathway
mTOR
MigraineFSGSCrohn's
Development Pipeline
Preclinical
Dec 2020
→ Sep 2026
PreclinicalCurrent
NCT04555445
1,087 pts·Migraine
2020-12→2026-09·Terminated
1,087 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-09-105mo awayInterim· Migraine
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2026-09-10 · 5mo away
Migraine
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04555445 | Preclinical | Migraine | Terminated | 1087 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin |